| 摘要 |
The present invention provides a useful medicament for the treatment and/or prophylaxis of a disease associated with the enhancement of OPN production including cancer, which comprises a compound of formula:;;wherein R1, R2, R3, R4, R5, R6, R7, m, n, p, X, and Y are as defined in the specification, a pharmaceutically acceptable salt thereof. |
| 主权项 |
1. A compound of formula:wherein
R1 and R3 are independently hydrogen atom, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, C3-8 heterocycloalkyl, C6-10 aryl, or 5- to 10-membered heteroaryl wherein the C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, C3-8 heterocycloalkyl, C6-10 aryl, and 5- to 10-membered heteroaryl independently may be optionally substituted with one group or the same or different two or more groups selected independently from the group consisting of halogen, hydroxy, mercapto, cyano, nitro, amino, mono- or di-C1-6 alkylamino, C1-4 acyl, C1-4 acylamino, C1-4 alkylsulfonyl, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C2-6 alkenyl, C2-6 alkynyl, and —OR5 at any replaceable positions; R2 is hydrogen atom, amino, amino substituted with one or two independently-selected C1-6 alkyl, hydroxy, or C1-6 alkoxy; R4 is hydrogen atom, halogen, amino, amino substituted with one or two independently-selected C1-6 alkyl, C1-6 alkyl, or C1-6 haloalkyl; R5 is C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, C3-8 heterocycloalkyl, C6-10 aryl, or 5- to 10-membered heteroaryl wherein the C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, C3-8 heterocycloalkyl, C6-10 aryl, and 5- to 10-membered heteroaryl may be optionally substituted with one group or the same or different two or more groups selected independently from the group consisting of halogen, hydroxy, mercapto, cyano, nitro, amino, mono- or di-C1-6 alkylamino, C1-4 acyl, C1-4 acylamino, C1-4 alkylsulfoxy, C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C2-6 alkenyl, and C2-6 alkynyl at any replaceable positions; R6 and R7 are independently hydrogen atom or C1-4 alkyl; n is 0 to 4, provided that when n is 1 to 4 and R6 is C1-4 alkyl, the terminal carbon atom of R6 may be combined with any one carbon atom of the alkylene group in the parenthesis for n to form a 4- to 6-membered ring; m is 0 or 1; p is 0 or 1; X is O, or when p is 0 and R2 is amino or substituted amino which is linked at the 2-position of the benzene ring, X may be CH connecting the nitrogen atom in R2 to form a pyrrole ring; and Y is CH2 or NH;or a pharmaceutically acceptable salt thereof, provided that the following compound is excluded:N-(3-(2-amino-3-(4-hydroxyphenoxy)phenyl)-3-oxopropyl)-4-hydroxybenzamide. |
